Pancrelipase
From Wikipedia, the free encyclopedia
|
Pancrelipase
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C5850H8902N1606O1739S49 |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Pancrelipase is a form of enzyme therapy for the treatment of various digestive disorders, primarily Exocrine pancreatic insufficiency. It is a mixture of three digestive enzymes, amylase, protease (peptidase), and lipase, which are normally produced by the pancreas. Pancrelipase is used by people with cystic fibrosis whose pancreatic ducts are blocked with mucus. The blockage prevents digestive enzymes that are made by the pancreas from reaching the intestines, where they are needed for digestion. This is also used with people with Chronic pancreatitis.
 |
This medical treatment article is a stub. You can help Wikipedia by expanding it. |
